PriceTargets.com logo

XOMA - XOMA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $78.50
  • Forecasted Upside: 161.75%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$29.99 As of 11/21/2024 12:20 PM ET
▼ -0.03 (-0.10%)

This chart shows the closing price for XOMA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New XOMA Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XOMA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XOMA

Analyst Price Target is $78.50
▲ +161.75% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for XOMA in the last 3 months. The average price target is $78.50, with a high forecast of $117.00 and a low forecast of $40.00. The average price target represents a 161.75% upside from the last price of $29.99.

This chart shows the closing price for XOMA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in XOMA. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/23/2024HC WainwrightReiterated RatingBuy ➝ Buy$117.00 ➝ $117.00
9/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$117.00 ➝ $117.00
8/15/2024HC WainwrightBoost TargetBuy ➝ Buy$74.00 ➝ $117.00
7/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$74.00 ➝ $74.00
5/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$74.00 ➝ $74.00
5/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$74.00
4/29/2024Leerink PartnrsReiterated RatingOutperform
4/29/2024Leerink PartnersInitiated CoverageOutperform$40.00
4/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$74.00
2/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$74.00
12/22/2023HC WainwrightReiterated RatingBuy ➝ Buy$74.00
9/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$74.00
8/9/2023HC WainwrightBoost TargetBuy ➝ Buy$69.00 ➝ $74.00
3/10/2023HC WainwrightReiterated RatingBuy$69.00
5/2/2022HC WainwrightReiterated RatingBuy$69.00
10/8/2021HC WainwrightBoost TargetBuy$56.00 ➝ $69.00
9/9/2021AegisLower TargetBuy$60.00 ➝ $56.00
9/7/2021WedbushDowngradeOutperform ➝ Neutral$22.00
6/29/2021AegisInitiated CoverageBuy$60.00
1/19/2021HC WainwrightBoost TargetBuy$30.00 ➝ $56.00
11/25/2020WedbushReiterated RatingBuy$36.00
8/25/2020WedbushReiterated RatingOutperform
5/5/2020WedbushReiterated RatingBuy$29.00
5/5/2020HC WainwrightReiterated RatingBuy$30.00
3/23/2020WedbushReiterated RatingBuy$29.00
3/9/2020HC WainwrightReiterated RatingBuy$30.00
12/6/2019HC WainwrightReiterated RatingBuy$30.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.55 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 4 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 4 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

XOMA logo
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Read More

Today's Range

Now: $29.99
Low: $29.99
High: $30.43

50 Day Range

MA: $28.88
Low: $25.48
High: $32.46

52 Week Range

Now: $29.99
Low: $14.33
High: $33.78

Volume

1,668 shs

Average Volume

21,683 shs

Market Capitalization

$353.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.9

Frequently Asked Questions

What sell-side analysts currently cover shares of XOMA?

The following sell-side analysts have issued reports on XOMA in the last twelve months: HC Wainwright, Leerink Partners, Leerink Partnrs, and StockNews.com.
View the latest analyst ratings for XOMA.

What is the current price target for XOMA?

0 Wall Street analysts have set twelve-month price targets for XOMA in the last year. Their average twelve-month price target is $78.50, suggesting a possible upside of 161.5%. HC Wainwright has the highest price target set, predicting XOMA will reach $117.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $40.00 for XOMA in the next year.
View the latest price targets for XOMA.

What is the current consensus analyst rating for XOMA?

XOMA currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe XOMA will outperform the market and that investors should add to their positions of XOMA.
View the latest ratings for XOMA.

What other companies compete with XOMA?

Other companies that are similar to XOMA include Progenics Pharmaceuticals, Osmotica Pharmaceuticals, Cue Biopharma, TherapeuticsMD and Myriad Genetics. Learn More about companies similar to XOMA.

How do I contact XOMA's investor relations team?

XOMA's physical mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company's listed phone number is (510) 204-7200 and its investor relations email address is [email protected]. The official website for XOMA is www.xoma.com. Learn More about contacing XOMA investor relations.